Avoidance of renal toxicity by 24-hour infusion of cisplatin
Bozzino, J.M.; Prasad, V.; Koriech, O.M.
Cancer Treatment Reports 65(3-4): 351-352
1981
ISSN/ISBN: 0361-5960 PMID: 7195304 Document Number: 177509
Document emailed within 1 workday
Related Documents
Donehower, R.C.; Karp, J.E.; Burke, P.J. 1986: Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion Cancer Treatment Reports 70(9): 1059-1065Mross, K.; Bewermeier, P.; Reifke, J.; Krüger, W.; Stockschläder, M.; Zander, A.; Hossfeld, D.K. 1994: Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion Bone Marrow Transplantation 13(4): 423-430
Kormos, R.L.; Trento, A.; Hardesty, R.L.; Griffith, B.P.; Thompson, M.; Bahnson, H.T. 1987: Avoidance of perioperative renal toxicity by a modified immunosuppression protocol Transplantation Proceedings 19(1 Part 3): 2525-2526
Brillet, G.; Deray, G.; Bunker, D.; Ben Hmida, M.; Baumelou, A.; Jacobs, C. 1991: Can cisplatin renal toxicity be prevented? Nephrologie 12(3): 143-146
Noori, S.; Mahboob, T. 2012: Role of electrolytes disturbances and Na(+)-K(+)-ATPase in cisplatin - induced renal toxicity and effects of ethanolic extract of Cichorium intybus Pakistan Journal of Pharmaceutical Sciences 25(4): 857-862
Tsuya, H.; Hato, T.; Murase, K.; Sato, T.; Kaneda, N.; Takahashi, C.; Takeuchi, T.; Shimokawa, K. 1998: A case of renal pelvic cancer with recurrence of liver metastasis showing partial response by injection of methotrexate and intraarterial infusion of cisplatin and pirarubicin Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(7): 1079-1081
Charoenvidhya, D.; Manotaya, S. 2013: Magnesium sulfate maintenance infusion in women with preeclampsia: a randomized comparison between 2 gram per hour and 1 gram per hour Journal of the Medical Association of Thailand 96(4): 395-398
Müller, P.H.; Egberts, E.H.; Held, W.; Junger, K.; Schmülling, R.; Prestele, H.; Horbach, L.; Malchow, H. 1981: Carbohydrate infusion in internal diseases. a comparative study of metabolically healthy persons and liver disease and diabetic patients. III. Glucose infusion over a 48-hour period Infusionstherapie und Klinische Ernahrung 8(6): 266-269
Iobst, W.F.; Bridges, C.R.; Regan-Smith, M.G. 1989: Antirheumatic agents: CNS toxicity and its avoidance Geriatrics 44(4): 95; 99
Wallace, C.A.; Sherry, D.D. 1995: A practical approach to avoidance of methotrexate toxicity Journal of Rheumatology 22(6): 1009-1012
Ogilvie, G.K.; Fettman, M.J.; Jameson, V.J.; Walters, L.M.; Lafferty, M.H.; Cooper, M.F.; Powers, B.E.; Ciekot, P.A.; Atwater, S.W.; Withrow, S.J. 1992: Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs American Journal of Veterinary Research 53(9): 1666-1669
Nakamura, K.; Akutsu, S.; Matsumoto, H.; Samura, K.; Nakata, Y.; Asano, M.; Hirata, A.; Ishikawa, H.; Matsuzaki, M. 1982: Toxicological study of amikacin following intravenous drip infusion. 1. Acute toxicity in rats, rabbits and dogs, and subacute toxicity in rabbits Japanese Journal of Antibiotics 35(8): 2048-2067
Chahinian, A.P.; Nogeire, C.; Ohnuma, T.; Greenberg, M.L.; Sivak, M.; Jaffrey, I.S.; Holland, J.F. 1979: Phase I study of weekly maytansine given by iv bolus or 24-hour infusion Cancer Treatment Reports 63(11-12): 1953-1960
Grunberg, S.M.; Kempf, R.A.; Venturi, C.L.; Mitchell, M.S. 1987: Phase i study of recombinant beta-interferon given by four-hour infusion Cancer Research 47(4): 1174-1178
Ohnuma, T.; Norton, L.; Andrejczuk, A.; Holland, J.F. 1985: Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans Cancer Research 45(1): 464-469
Greco, F.A.; Hainsworth, J.D. 1995: One-hour paclitaxel infusion schedules: a phase I/Ii comparative trial Seminars in Oncology 22(3 Suppl 6: 118-123
Shin, S.J.; Lee, Y.J.; Hsiao, P.J.; Lin, L.; Wang, S.F.; Chang, F.T.; Chuang, F.J.; Tsai, J.H. 1990: The variability of 24-hour, overnight 12-hour, and morning one-hour, urinary albumin excretion in normoalbuminuric and microalbuminuric hospitalized diabetics Gaoxiong Yi Xue Ke Xue Za Zhi 6(9): 511-516
Hayase, R.; Yamamoto, J.; Yamamoto, M.; Kodama, J.; Tamada, T.; Kudoh, T. 1995: Pt levels following the infusion of daily low-dose cisplatin Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 565-568
Lomen, P.L.; Baker, L.H.; Neil, G.L.; Samson, M.K. 1975: Phase i study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days Cancer ChemoTherapy Reports 59(6): 1123-1126
Chen, J.T.; Kurokawa, Y.; Nakayama, K.; Saito, K.; Sakamoto, K.; Fukuda, K.; Hirai, Y.; Hamada, T.; Fujimoto, I.; Yamauchi, K. 1987: The effect of bismuth subnitrate on cisplatin toxicity Nihon Sanka Fujinka Gakkai Zasshi 39(5): 815-822